Abstract
Bone marrow (BM) suppression is an important dose-limiting side effect of chemotherapy and radiotherapy for cancer. Although acute myelosuppression is an immediate concern for patients undergoing cancer therapy, its management has been improved significantly in recent years by the use of various hematopoietic growth factors. However, many patients receiving chemotherapy and/or ionizing radiation (IR) also develop residual (or long-term) BM injury (a sustained decrease in HSC reserves due to an impairment in HSC self-renewal) after the recovery from acute myelosuppression. Unlike acute myelosuppression, residual BM injury is latent and long lasting and shows little tendency for recovery. Following additional hematopoietic stress such as subsequent cycles of consolidation cancer treatment or autologous BM transplantation, residual BM injury can deteriorate to become a hypoplastic or myelodysplastic syndrome. This article review some of the new developments in elucidating the cellular and molecular mechanisms whereby chemotherapy and radiotherapy cause residual BM injury. Particularly, we discuss the role of induction of hematopoietic stem cell (HSC) senescence via the p53-p21Cip1/Waf1 and/or p16Ink4a-RB pathways in the induction of the injury and the therapeutic potential of molecularly targeting these pathways for amelioration of chemotherapy- and radiotherapy-induced long-term BM toxicity.
Keywords: Ionizing radiation, chemotherapy, myelosuppression, hematopoietic stem cells, senescence
Current Cancer Therapy Reviews
Title: Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Volume: 2 Issue: 3
Author(s): Yong Wang, Virginia Probin and Daohong Zhou
Affiliation:
Keywords: Ionizing radiation, chemotherapy, myelosuppression, hematopoietic stem cells, senescence
Abstract: Bone marrow (BM) suppression is an important dose-limiting side effect of chemotherapy and radiotherapy for cancer. Although acute myelosuppression is an immediate concern for patients undergoing cancer therapy, its management has been improved significantly in recent years by the use of various hematopoietic growth factors. However, many patients receiving chemotherapy and/or ionizing radiation (IR) also develop residual (or long-term) BM injury (a sustained decrease in HSC reserves due to an impairment in HSC self-renewal) after the recovery from acute myelosuppression. Unlike acute myelosuppression, residual BM injury is latent and long lasting and shows little tendency for recovery. Following additional hematopoietic stress such as subsequent cycles of consolidation cancer treatment or autologous BM transplantation, residual BM injury can deteriorate to become a hypoplastic or myelodysplastic syndrome. This article review some of the new developments in elucidating the cellular and molecular mechanisms whereby chemotherapy and radiotherapy cause residual BM injury. Particularly, we discuss the role of induction of hematopoietic stem cell (HSC) senescence via the p53-p21Cip1/Waf1 and/or p16Ink4a-RB pathways in the induction of the injury and the therapeutic potential of molecularly targeting these pathways for amelioration of chemotherapy- and radiotherapy-induced long-term BM toxicity.
Export Options
About this article
Cite this article as:
Wang Yong, Probin Virginia and Zhou Daohong, Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy, Current Cancer Therapy Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339406777934717
DOI https://dx.doi.org/10.2174/157339406777934717 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets Liposomes Containing Gadodiamide: Preparation, Physicochemical Characterization, and In Vitro Cytotoxic Evaluation
Current Drug Delivery How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Established and Emerging Fluorescence-Based Assays for G-Protein Function: Ras-Superfamily GTPases
Combinatorial Chemistry & High Throughput Screening Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Current Cancer Drug Targets Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Salviabased Drug Discovery
Current Drug Metabolism The Effect on the Intestine of Some Fungal Toxins: The Trichothecenes
Current Immunology Reviews (Discontinued) Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
Anti-Cancer Agents in Medicinal Chemistry A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer
Current Cancer Drug Targets